SENSEX NIFTY

Novo Nordisk

Oct 09, 2013 at 13:00 | Source: Reuters
The concept of oral insulin as a way to relieve people with type 1 diabetes of several daily injections has been around since the 1930s.
Sep 03, 2013 at 21:14 | Source: CNBC-TV18
Danish drug maker Novo Nordisk is all set to launch its ultra long-lasting insulin injection, brand named Tresiba, in India by the end of this year.
Feb 14, 2013 at 10:18 | Source: Moneycontrol.com
Biocon shares rose 2 percent in morning trade on Thursday after the biotechnology company said it has enhanced its partnership with pharma major Mylan through a strategic collaboration for insulin products.
Apr 18, 2012 at 14:20 | Source: Moneycontrol.com
Shares of pharma major Sun Pharmaceutical Industries rose over 2.5% on Wednesday, after US Supreme Court gave a verdict in favour of its arm Caraco Pharmaceutical Laboratories in the ongoing battle with Novo Nordisk for a generic version of diabetic drug Prandin.
Apr 17, 2012 at 20:36 | Source: Reuters
The US Supreme Court ruled on Tuesday in favor of a generic drugmaker in a case over how companies can fight brand-name rivals in an effort to get their cheaper medicines to market.
Apr 16, 2012 at 18:54 | Source: CNBC-TV18
Novo Nordisk, in association with CNBC-TV18, presents "Improving Control of Diabetes Pandemic in India". In this discussion, experts address the challenges and management of diabetes in India.
Mar 20, 2012 at 21:43 | Source: CNBC-TV18
Multi-national drug companies are queuing up to enter India and tap its growing anti-diabetes drug market. But Novo Nordisk, which has been in the Indian insulin market for 75 years, is not worried, reports CNBC-TV18's Archana Shukla.
Mar 13, 2012 at 10:30 | Source: Moneycontrol.com
Pfizer - Biocon alliance has called off due to individual priorities and in Shares of Biocon fell more than 8% on Tuesday morning after US pharma major Pfizer scrapped a deal to sell insulin products made by the Bangalore-based biotechnology company.
Mar 12, 2012 at 21:59 | Source: CNBC-TV18
The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.
Dec 12, 2011 at 21:57 | Source: CNBC-TV18
A breakthrough in oral insulin will mean doing away with insulin injections all together which explains the flurry of activity in the field. CNBC-TV18's Archana Shukla reports on just how far this research has progressed.
Messages on Novo Nordisk »

sanecounsel

Platinum Member

73 Followers

Biocon  

Look at contributions made by Novo Nordisk,Roche and Sanofi to Democratic (&)republican parties - Who said affordability is key issue for legislators ? Perhaps its expediency or even morphed sense of nationalism.Its this inability to manipulate the political system by means hook or crook

12.26 PM Feb 22nd

sanecounsel

Platinum Member

73 Followers

Biocon  

The bad news is that though Biocon is in the right this can distract , delay even divert at least in the short term.Not sure if Biocon has a smart legal team as this was not part of their business model at all unlike a lupin or a reddys.Today Roche tomorrow Novo Nordisk can use legal route to delay

10.52 PM Feb 8th

Web Messenger

Platinum Member

228747 Followers

Aurobindo Pharm  

Source:The Hindu BusinessLine - Aurobindo Pharma Ld has received the final approval from the US Food Drug Administration (USFDA) to manufacture and market Repaglinide tablets. The product is ready for launch. The tablets are the generic equivalent of Novo Nordisk Inc’s Prandin tablets

7.10 PM Jan 23rd

sanecounsel

Platinum Member

73 Followers

Biocon  

-LA ROCHE LTD. (DISETRONIC MEDICAL SYSTEMS AG),GENEREX BIOTECHNOLOGY CORPORATION,HALOZYME THERAPEUTICS INC.,INSULINE MEDICAL,INSULUTION ABM, LIFESCAN,MANNKIND,MARINA BIOTECH INC.,MEDTRONIC INC., MICROPORT SCIENTIFIC CORPORATION,MIDASOL THERAPEUTICS (JOINT VENTURE OF MIDATECH LTD. AND MONOSOL RX),NOVO

11.47 AM Sep 10th 2013

Web Messenger

Platinum Member

228747 Followers

News Now  

Source:The Hindu BusinessLine - The world’s largest insulin player Novo Nordisk today said it is launching long-lasting insulin injection Tresiba in the country soon. “Tresiba (insulin degludec) — a new basal insulin for adult patients with type 1 and type 2 diabetes to be available in India

7.58 PM Sep 2nd 2013

koppik

Gold Member

4 Followers

Biocon  

mentions that while Oramed appears to be the furthest along in oral insulin R&D, Novo Nordisk is right on its heels, earlier this year completing a Phase I trial of a similar treatment co-developed with Merrion Pharmaceuticals. it also mentions that Bristol-Myers Squibb has teamed up with India`s Biocon

3.45 PM Jul 19th 2013

koppik

Gold Member

4 Followers

Just Posted  

mentions that while Oramed appears to be the furthest along in oral insulin R&D, Novo Nordisk is right on its heels, earlier this year completing a Phase I trial of a similar treatment co-developed with Merrion Pharmaceuticals. it also mentions that Bristol-Myers Squibb has teamed up with India`s Biocon

3.43 PM Jul 19th 2013

omsairam666

Gold Member

5 Followers

Sun Pharma Adv  

Applications (ANDA) for generic version of Prandein, Repaglinide tablets. Repaglinide tablets, 1 mg and 2 mg are therapeutic equivalents of Novo Nordisk�s Prandein tablets. These tablets have annual sales of approximately USD 200 million in the US. Repaglinide tablets are indicated as an adjunct to diet

12.41 PM Jul 15th 2013

SRINIVASA HYD

Platinum Member

620 Followers

Commodities  

Elsewhere, Novo Nordisk climbed 0.84% after the Danish drugmaker said tests with its liraglutide treatment showed an 8% weight-loss for overweight patients without diabetes, compared with a 2.6% weight loss for a placebo

3.50 PM May 24th 2013

Web Messenger

Platinum Member

228747 Followers

Pharmaceuticals - Sector  

Source:Business Week - Novo Nordisk A/S had the biggest drop in more than a decade, losing about $15 billion of market value, after U.S. regulators rejected its new insulin. The Food and Drug Administration demanded a new study to assess the heart risk of taking Novo's

5.39 PM Feb 12th 2013

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.